Source comparison
CJC-1295 Gene Expression: Research Comparison
CJC-1295 (with DAC) GHRH receptor (pituitary somatotrophs) GH1 mRNA +200–400% at 48–72h 6–8 days 6–8 days post-injection Gold standard for sustained transcriptional GH upregulation; feed-forward receptor density increase compounds effect over time Ipamorelin G
This comparison does not assign a generated winner or score.
- CJC-1295 (with DAC)
- GHRH receptor (pituitary somatotrophs)
- GH1 mRNA +200–400% at 48–72h
- 6–8 days
- 6–8 days post-injection
- Gold standard for sustained transcriptional GH upregulation; feed-forward receptor density increase compounds effect over time
- Ipamorelin
- Ghrelin receptor (GHSR1a)
- GH1 mRNA +80–120% at 2–4h
- 2 hours
- <24 hours
- Acute pulsatile effect with minimal transcriptional persistence; useful for circadian-aligned protocols
- Sermorelin
- GH1 mRNA +150–200% at 1–2h
- 8–12 minutes
- <12 hours
- Mimics natural GHRH pulse; no sustained receptor occupancy or prolonged mRNA elevation
- GHRP-2
- GH1 mRNA +100–140% at 2–4h
- 20–30 minutes
- <18 hours
- Strong acute pulse but no hepatic IGF-1 gene persistence beyond 18–24 hours
- Tesamorelin
- GH1 mRNA +180–220% at 2–4h
- 26–38 minutes
- FDA-approved for lipodystrophy; shorter half-life limits transcriptional duration compared to CJC-1295
- CJC-1295 stands apart in duration and magnitude of transcriptional change. Peptides like ipamorelin and GHRP-2 trigger acute growth hormone secretion pulses without sustained mRNA upregulation. Gene expression returns to baseline within hours. Sermorelin mimics endogenous GHRH but clears too quickly to drive prolonged transcriptional activation. Tesamorelin occupies a middle ground with moderate mRNA elevation and clinical approval, but lacks the feed-forward receptor upregulation seen with CJC-1295.